<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1157">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146089</url>
  </required_header>
  <id_info>
    <org_study_id>2007973</org_study_id>
    <secondary_id>K99HL130339</secondary_id>
    <secondary_id>R00HL130339</secondary_id>
    <nct_id>NCT05146089</nct_id>
  </id_info>
  <brief_title>Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences</brief_title>
  <official_title>Reflex Responses to Intermittent Hypoxia in Humans: Mechanisms and Consequences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project is to better understand the effect of intermittent hypoxia&#xD;
      (IH) on sympathetic neuronal discharge patterns in humans, as well as mechanisms that mediate&#xD;
      persistent sympathoexcitation with IH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep apnea is the most common form of sleep disordered breathing and patients with sleep&#xD;
      apnea exhibit persistent activation of the sympathetic nervous system. Sympathoexcitation is&#xD;
      also the final common pathway for a host of complications in conditions like obesity,&#xD;
      hypertension, sleep apnea, and heart failure and plays a significant role in predicting&#xD;
      negative clinical outcomes and deteriorating cardiovascular health. However, the mechanisms&#xD;
      of sympathoexcitation with sleep apnea are poorly understood and thus make effective&#xD;
      therapeutic approaches difficult to develop.&#xD;
&#xD;
      Intermittent hypoxia (IH) has been implicated in animal models as the primary stimulus for&#xD;
      evoking increases in sympathetic activity with recurrent apneas. Thus, the overall goal of&#xD;
      this application is to better understand the effect of IH on sympathetic discharge patterns&#xD;
      in humans as well as the mechanisms mediating persistent sympathoexcitation with IH. By&#xD;
      better understanding the effect of IH on sympathoexcitation, targeted therapeutic approaches&#xD;
      might be devised to mitigate the effects of sympathetic over-activity on the cardiovascular&#xD;
      system in conditions such as sleep apnea.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Actual">April 12, 2021</completion_date>
  <primary_completion_date type="Actual">September 8, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects will be asked to complete 1 1-hour screening visit, 1 overnight at-home monitoring, and 1 (women) or 2 (men) 5-hour study visits. Subjects will not be blinded to study condition and all subjects will serve as their own controls. All study visits will be separated by a minimum of 1 week and will occur at the same time of day.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle sympathetic nerve activity (MSNA)</measure>
    <time_frame>Change from baseline after hypoxia exposure</time_frame>
    <description>MSNA burst incidence (bursts/100 heart beats)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial blood pressure</measure>
    <time_frame>Change from baseline after hypoxia exposure</time_frame>
    <description>Systolic blood pressure, Diastolic blood pressure, Mean blood pressure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Sleep Apnea</condition>
  <condition>Healthy</condition>
  <condition>Vasoconstriction</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Men and women will be exposed to acute intermittent hypoxic episodes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxic exposure</intervention_name>
    <description>30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>modified Oxford test</intervention_name>
    <description>An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Bosentan 62.5 mg</intervention_name>
    <description>Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxic ventilatory response test</intervention_name>
    <description>Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.</description>
    <arm_group_label>Hypoxia Exposure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy adult men and women;&#xD;
&#xD;
          -  18-45 years of age;&#xD;
&#xD;
          -  BMI &lt;30 kg/m2;&#xD;
&#xD;
          -  non-pregnant/non-breastfeeding;&#xD;
&#xD;
          -  non-smokers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they are:&#xD;
&#xD;
          -  taking any medications known to affect the cardiovascular or autonomic nervous system&#xD;
             (e.g. alpha-blockers, beta-blockers, etc);&#xD;
&#xD;
          -  Apnea Hypopnea Index &gt;10 events/hr&#xD;
&#xD;
        Self-reported history of:&#xD;
&#xD;
          -  hepatic, renal, pulmonary, cardiovascular, or neurological disease;&#xD;
&#xD;
          -  stroke or neurovascular disease;&#xD;
&#xD;
          -  bleeding/clotting disorders;&#xD;
&#xD;
          -  sleep apnea or other sleep disorders;&#xD;
&#xD;
          -  diabetes;&#xD;
&#xD;
          -  smoking;&#xD;
&#xD;
          -  history of alcoholism or substance abuse;&#xD;
&#xD;
          -  hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline K Limberg, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Missouri</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Jacqueline K Limberg, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

